Relationship between NF1 and constitutive mismatch repair deficiency

Neurofibromatosis Type 1: Molecular and Cellular Biology

Volumn 9783642328640, Issue , 2012, Pages 235-251

  Wimmer, Katharina ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941024101     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-32864-0_16     Document Type: Chapter

References (78)

1. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, et al. (1993). Clues to the pathogenesis of familial colorectal cancer. Science 260: 812-816
2. Agostini M, Tibiletti MG, Lucci-Cordisco E, Chiaravalli A, Morreau H, Furlan D, Boccuto L, Pucciarelli S, Capella C, Boiocchi M, Viel A. (2005). Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol 100: 1886-1891
3. Allan JM, Travis LB. (2005). Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 5: 943-955
4. Alotaibi H, Ricciardone MD, Ozturk M. (2008). Homozygosity at variant MLH1 can lead to secondary mutation in NF1, neurofibromatosis type I and early onset leukemia. Mutat Res. 637: 209-214
5. Auclair J, Leroux D, Desseigne F, Lasset C, Saurin JC, Joly MO, Pinson S, Xu XL, Montmain G, Ruano E, Navarro C, Puisieux A, Wang Q. (2007). Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat. 28: 1084-1090
6. Baas AF, Gabbett M, Rimac M, Kansikas M, Raphael M, Nievelstein RA, Nicholls W, Offerhaus J, Bodmer D, Wernstedt A, Krabichler B, Strasser U, Nyström M, Zschocke J, Robertson SP, van Haelst MM, Wimmer K. (2012). Agenesis of the corpus callosum and gray matter heterotopia in three patients with constitutional mismatch repair deficiency syndrome. Eur J Hum Genet (in press)
7. Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH. (2002). Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70: 26-37
8. Bertholon J, Wang Q, Galmarini CM, Puisieux A. (2006). Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer 5: 29-34
9. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257
10. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C. (2011). Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 305: 2304-2310
11. Bougeard G, Charbonnier F, Moerman A, Martin C, Ruchoux MM, Drouot N, Frebourg T. (2003). Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet. 72: 213-216
12. De la Chapelle A. (2004). Genetic predisposition to colorectal cancer. Nat Rev Cancer 4: 769-780
13. De Rosa M, Fasano C, Panariello L, Scarano MI, Belli G, Iannelli A, Ciciliano F, Izzo P. (2000). Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene 19: 1719-1723
14. De Vos M, Hayward BE, Charlton R, Taylor GR, Glaser AW, Picton S, Cole TR, Maher ER, McKeown CM, Mann JR, Yates JR, Baralle D, Rankin J, Bonthron DT, Sheridan E. (2006). PMS2 mutations in childhood cancer. J Natl Cancer Inst 98: 358-361
15. Distelmaier F, Fahsold R, Reifenberger G, Messing-Juenger M, Schaper J, Schneider DT, Gobel U, Mayatepek E, Rosenbaum T. (2007). Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Childs Nerv Syst 23: 343-347
16. Durandy A. (2009). Immunoglobulin class switch recombination: study through human natural mutants. Philos Trans R Soc Lond B Biol Sci 364: 577-582
17. Durno CA, Holter S, Sherman PM, Gallinger S. (2010). The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol 105: 2449-2456
18. Durno CA, Aronson M, Tabori U, Malkin D, Gallinger S, Chan HS. (2012). Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 59: 652-656
19. Etzler J, Peyrl A, Zatkova A, Schildhaus HU, Ficek A, Merkelbach-Bruse S, Kratz CP, Attarbaschi A, Hainfellner JA, Yao S, Messiaen L, Slavc I, Wimmer K. (2008). RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. Hum Mutat 29: 299-305
20. Fedier A, Fink D. (2004). Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 24: 1039-1047
21. Felton KE, Gilchrist DM, Andrew SE. (2007). Constitutive deficiency in DNA mismatch repair. Clin Genet 71: 483-498
22. Gallinger S, Aronson M, Shayan K, Ratcliffe EM, Gerstle JT, Parkin PC, Rothenmund H, Croitoru M, Baumann E, Durie PR, Weksberg R, Pollett A, Riddell RH, Ngan BY, Cutz E, Lagarde AE, Chan HS. (2004). Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 126: 576-585
23. Gardes P, Forveille M, Alyanakian MA, Aucouturier P, Ilencikova D, Leroux D, Rahner N, Mazerolles F, Fischer A, Kracker S, Durandy A. (2012). Human MSH6 deficiency Is associated with impaired antibody maturation. J Immunol 188: 2023-2029
24. Giunti L, Cetica V, Ricci U, Giglio S, Sardi I, Paglierani M, Andreucci E, Sanzo M, Forni M, Buccoliero AM, Genitori L, Genuardi M. (2009). Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome. Eur J Hum Genet 17: 919-927
25. Glover TW, Stein CK, Legius E, Andersen LB, Brereton A, Johnson S. (1991). Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chrom Cancer 3: 62-70
26. Goel A, Nagasaka T, Hamelin R, Boland CR. (2010). An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5: e9393
27. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS. (2008). Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol 10: 93-97
28. Gutmann DH, Winkeler E, Kabbarah O, Hedrick N, Dudley S, Goodfellow PJ, Liskay RM. (2003). Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice. Oncogene 22: 4581-4585
29. Hegde MR, Chong B, Blazo ME, Chin LH, Ward PA, Chintagumpala MM, Kim JY, Plon SE, Richards CS. (2005). A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res 11: 4689-4693
30. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Moller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Brocker-Vriends AH, Vasen H. (2004). Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127: 17-25
31. Herkert JC, Niessen RC, Olderode-Berends MJ, Veenstra-Knol HE, Vos YJ, van der Klift HM, Scheenstra R, Tops CM, Karrenbeld A, Peters FT, Hofstra RM, Kleibeuker JH, Sijmons RH. (2011). Paediatric intestinal cancer and polyposis due to bi-Allelic PMS2 mutations: case series, review and follow-up guidelines. Eur J Cancer 47: 965-982
32. Huson SM. (2008). The neurofibromatoses: classification, clinical features and genetic counselling. In: Kaufmann D (ed) Neurofibromatoses, vol 16, Monographs in human genetics. Karger, Basel, pp 1-20
33. Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, Goumnerova LC, Irons MB, Ullrich NJ. (2010). Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54: 890-896
34. Jiricny J. (2006). The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7: 335-346
35. Jiricny J. (2006). MutLalpha: at the cutting edge of mismatch repair. Cell 126: 239-241
36. Johannesma P, van der Klift H, van Grieken N, Troost D, Te Riele H, Jacobs M, Postma T, Heideman D, Tops C, Wijnen J, Menko F. (2011). Childhood brain tumours due to germline bi-Allelic mismatch repair gene mutations. Clin Genet 80: 243-255
37. Kadyrov FA, Dzantiev L, Constantin N, Modrich P. (2006). Endonucleolytic function of MutLalpha in human mismatch repair. Cell 126: 297-308
38. Kets CM, Hoogerbrugge N, van Krieken JH, Goossens M, Brunner HG, Ligtenberg MJ. (2009). Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1AG of MSH2. Eur J Hum Genet 17: 159-164
39. Kratz CP, Holter S, Etzler J, Lauten M, Pollett A, Niemeyer CM, Gallinger S, Wimmer K. (2009). Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 46: 418-420
40. Kruger S, Kinzel M, Walldorf C, Gottschling S, Bier A, Tinschert S, von Stackelberg A, Henn W, Gorgens H, Boue S, Kolble K, Buttner R, Schackert HK. (2008). Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-Associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet. 16: 62-72
41. Leenen C, Geurts-Giele W, Dubbink H, Reddingius R, van den Ouweland A, Tops C, van de Klift H, Kuipers E, van Leerdam M, Dinjens W, Wagner A. (2011). Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic pms2 germline mutations. Clin Genet 80: 558-565
42. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296: 1507-1517
43. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW. (1996). Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2: 169-174
44. Lynch HT, de la Chapelle A. (2003). Hereditary colorectal cancer. N Engl J Med 348: 919-932
45. Lynch HT, Lynch JF, Attard TA. (2009). Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ 181: 273-280
46. Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, Lange BJ, Shannon KM. (1997). Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79: 1438-1446
47. Menko FH, Kaspers GL, Meijer GA, Claes K, van Hagen JM, Gille JJ. (2004). A homozygous MSH6 mutation in a child with café-Au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer 3: 123-127
48. Ostergaard JR, Sunde L, Okkels H. (2005). Neurofibromatosis von Recklinghausen type 1 phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am J Med Genet A 139: 96-105, discussion 196
49. Peltomaki P. (2003). Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21: 1174-1179
50. Perilongo G, Felix CA, Meadows AT, Nowell P, Biegel J, Lange BJ. (1993). Sequential development of Wilms tumor, T-cell acute lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: a clinical and cytogenetic case report. Leukemia 7: 912-915
51. Péron S, Metin A, Gardes P, Alyanakian MA, Sheridan E, Kratz CP, Fischer A, Durandy A. (2008). Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 205: 2465-2472
52. Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel Doeberitz M, Ruschoff J, Loeffler M, Schackert HK. (2004). Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol. 22: 4486-4494
53. Plaschke J, Linnebacher M, Kloor M, Gebert J, Cremer FW, Tinschert S, Aust DE, von Knebel DM, Schackert HK. (2006). Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-Associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet 14: 561-566
54. Poley JW, Wagner A, Hoogmans MM, Menko FH, Tops C, Kros JM, Reddingius RE, Meijers-Heijboer H, Kuipers EJ, Dinjens WN. (2007). Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer 109: 2349-2356
55. Rahner N, Hoefler G, Hogenauer C, Lackner C, Steinke V, Sengteller M, Friedl W, Aretz S, Propping P, Mangold E, Walldorf C. (2008). Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. Am J Med Genet A 146A: 1314-1319
56. Ricciardone MD, Ozcelik T, Cevher B, Ozdag H, Tuncer M, Gurgey A, Uzunalimoglu O, Cetinkaya H, Tanyeli A, Erken E, Ozturk M. (1999). Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 59: 290-293
57. Ripperger T, Beger C, Rahner N, Sykora KW, Bockmeyer CL, Lehmann U, Kreipe HH, Schlegelberger B. (2010). Constitutional mismatch repair deficiency and childhood leukemia/.lymphoma - report on a novel biallelic MSH6 mutation. Haematologica 95: 841-844
58. Scott RH, Homfray T, Huxter NL, Mitton SG, Nash R, Potter MN, Lancaster D, Rahman N. (2007). Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations. J Med Genet 44: e83
59. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N. (2007). Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 4: 130-134
60. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135: 419-428
61. Shannon KM, Watterson J, Johnson P, O'Connell P, Lange B, Shah N, Steinherz P, Kan YW, Priest JR. (1992). Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 79: 1311-1318
62. Sjursen W, Bjornevoll I, Engebretsen LF, Fjelland K, Halvorsen T, Myrvold HE. (2009). A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts. Fam Cancer 8: 179-186
63. Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, Shannon KM. (2006). Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 108: 1684-1689
64. Stojic L, Brun R, Jiricny J. (2004). Mismatch repair and DNA damage signalling. DNA Repair (Amst) 3: 1091-1101
65. Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. (2004). Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 144: 666-668
66. Tan TY, Orme LM, Lynch E, Croxford MA, Dow C, Dewan PA, Lipton L. (2008). Biallelic PMS2 mutations and a distinctive childhood cancer syndrome. J Pediatr Hematol Oncol 30: 254-257
67. Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM. (2001). Café-Au-lait spots and early onset colorectal neoplasia: a variant of HNPCC?. Fam Cancer 1: 101-105
68. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268
69. Uyttebroeck A, Legius E, Brock P, Van de Cassey W, Casaer P, Casteels-Van Daele M. (1995). Consecutive glioblastoma and B cell non-Hodgkin's lymphoma in a young child with von Recklinghausen's neurofibromatosis. Med Pediatr Oncol 24: 46-49
70. van der Klift HM, Tops CM, Bik EC, Boogaard MW, Borgstein AM, Hansson KB, Ausems MG, Gomez Garcia E, Green A, Hes FJ, Izatt L, van Hest LP, Alonso AM, Vriends AH, Wagner A, van Zelst-Stams WA, Vasen HF, Morreau H, Devilee P, Wijnen JT. (2010). Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. Hum Mutat 31: 578-587
71. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Moller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J. (2007). Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44: 353-362
72. Vaughn CP, Hart KJ, Samowitz WS, Swensen JJ. (2011). Avoidance of pseudogene interference in the detection of 30 deletions in PMS2. Hum Mutat 32: 1063-1071
73. Wagner A, Reddingius RE, Kros JM, Dinjens WN, Sleddens H, Hoogmans MM, v. d. Velde A, Tops C, Wijnen J, Meijers-Heijboer H, Menko F. (2003). Wilms tumor and glioblastoma in a child with a double MLH1 germline mutation. Fam Cancer 2(Suppl 1): 57
74. Wang Q, Lasset C, Desseigne F, Frappaz D, Bergeron C, Navarro C, Ruano E, Puisieux A. (1999). Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 59: 294-297
75. Wang Q, Montmain G, Ruano E, Upadhyaya M, Dudley S, Liskay RM, Thibodeau SN, Puisieux A. (2003). Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet 112: 117-123
76. Wernstedt A, Valtorta E, Armelao F, Togni R, Girlando S, Baudis M, Heinimann K, Messiaen L, Staehli N, Zschocke J, Marra G, Wimmer K. (2012). Improved multiplex ligation-dependent probe amplification analysis identifies a deleterious PMS2 allele generated by recombination with crossover between PMS2 and PMS2CL. Genes Chromosomes Cancer 51: 819-831
77. Whiteside D, McLeod R, Graham G, Steckley JL, Booth K, Somerville MJ, Andrew SE. (2002). A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-Au-lait spots. Cancer Res 62: 359-362
78. Wimmer K, Etzler J. (2008). Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?. Hum Genet 124: 105-122